Latest Diabetic retinopathy Stories

Older people are at increased risk of several eye diseases, including age-related macular degeneration (AMD), cataracts, and glaucoma. AMD can cause profound loss of central vision due to the breakdown of the eye's light-sensing cells in the retina. Cataracts cloud vision through clumping of proteins in the eye's lens. Glaucoma damages the optic nerve often due to increased pressure in the eye. The increase in type 2 diabetes, which is more common in older Americans and especially minorities,...

MOUNTAIN VIEW, Calif., Oct. 10, 2011 /PRNewswire/ -- IRIDEX Corporation (Nasdaq: IRIX) (the "Company") today announced that Dominik Beck has been named President and Chief Executive Officer effective today. Dr. Beck replaces Theodore A. Boutacoff, a co-founder of IRIDEX who will become Chief Technology Officer, and will also replace Mr. Boutacoff on the IRIDEX Board of Directors. Dr. Beck, 47, has spent the majority of his career in leadership and management roles at innovative and growing...

NEW YORK, Oct. 4, 2011 /PRNewswire/ -- At the invitation of the Regional President of La Libertad, the Ministry of Health, Instituto Regional de Oftalmologia (IRO) and sponsored by FedEx, ORBIS International landed its flagship Flying Eye Hospital - a converted DC-10 aircraft, flown by volunteer FedEx pilots, containing a state-of-the-art surgical and teaching facility - in Trujillo, Peru. During the next few weeks, the ORBIS medical team will conduct an intensive skills-exchange program...

VANCOUVER, Sept. 26, 2011 /PRNewswire/ - iCo Therapeutics Inc. (TSXV: ICO) today announced that the company has entered into a research collaboration agreement with JDRF, the worldwide leader for research to cure, treat, and prevent type 1 diabetes (T1D), to support the previously announced Phase 2 investigator sponsored clinical trial investigating iCo-007 in Diabetic Macular Edema (DME). DME is a major complication of diabetes and a leading cause of blindness in adults. In DME,...

IQWiG publishes final report on literature search / No major changes necessary On 22 August 2011, the German Institute for Quality and Efficiency in Health Care (IQWiG) published the results of a literature search for evidence-based clinical practice guidelines on the treatment of people with diabetes mellitus type 1. The aim of the report is to identify those recommendations from current guidelines of high methodological quality that may be relevant for the planned revision of the...

A simple finger prick test during routine eye examinations at high street opticians could help to identify millions of people with previously undiagnosed Type 2 diabetes, according to new research. The researchers suggest earlier diagnosis could set people on the road to better management of the disease, which is the leading cause of blindness in the working age population, and that this could ultimately result in cost-savings for the NHS. The Durham University study suggests that...

SOUTHAMPTON, England, August 23, 2011 /PRNewswire/ -- KalVista Pharmaceuticals ("KalVista"), a new ophthalmology company with a focus on diabetic macular edema (DME), has raised GBP8 million in a series A round from leading life sciences investors Novo A/S and SV Life Sciences. The Company is developing novel, small molecule plasma kallikrein inhibitors, which represent a new approach to the treatment of DME, a leading cause of adult visual loss in developed countries...

TARRYTOWN, N.Y., Aug. 17, 2011 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced that clinical data from four separate clinical studies of EYLEA(TM) (aflibercept injection) will be presented at the upcoming American Society of Retina Specialists (ASRS) meeting on Sunday, August 21 and Monday, August 22, 2011 in Boston, Massachusetts. The presentations are: "Analysis of 2,457 Patients in the Phase 3 VIEW 1 and VIEW 2 Studies Comparing VEGF Trap-Eye and...

ANN ARBOR, Mich., Aug. 17, 2011 /PRNewswire-USNewswire/ -- Many Americans suffer from diabetes and hypertension and, according to a study by researchers at the University of Michigan Kellogg Eye Center, these individuals may have an increased risk of developing open-angle glaucoma (OAG). Joshua D. Stein, M.D., M.S., a glaucoma specialist at Kellogg, led a research team that recently reviewed billing records of more than 2 million people aged 40 and older who were enrolled in a managed care...

TARRYTOWN, N.Y., Aug. 16, 2011 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced that it has received notification from the U.S. Food and Drug Administration (FDA) that the agency has extended its target date to complete the priority review of the EYLEA Biologics License Application (BLA) for the treatment of neovascular age-related macular degeneration (wet AMD) to November 18, 2011, which is a three month extension from the original Prescription Drug User Fee...